scholarly journals CT-Guided 125I Brachytherapy in the Treatment of Hepatocellular Carcinoma Refractory to Conventional Transarterial Chemoembolization: A Pilot Study

2021 ◽  
Vol Volume 13 ◽  
pp. 3317-3326
Author(s):  
Xinjian Xu ◽  
Yiwen Ding ◽  
Tianfan Pan ◽  
Feng Gao ◽  
Xiangzhong Huang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Pilot Study ◽  
Transarterial Chemoembolization ◽  
Ct Guided ◽  
125I Brachytherapy

The pilot study: a novel transarterial chemoembolization using degradable starch microspheres for hepatocellular carcinoma

Kanzo ◽  
2008 ◽  
Vol 49 (1) ◽  
pp. 25-27 ◽  
Author(s):  
Takahiro Yamasaki ◽  
Issei Saeki ◽  
Yohei Harima ◽  
Kohsuke Okita ◽  
Makoto Segawa ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Pilot Study ◽  
Transarterial Chemoembolization ◽  
Degradable Starch Microspheres

scholarly journals DC Bead Transarterial Chemoembolization Is Effective in Hepatocellular Carcinoma Refractory to Conventional Transarteral Chemoembolization: A Pilot Study

Gut and Liver ◽  
2013 ◽  
Vol 7 (1) ◽  
pp. 89-95 ◽  
Author(s):  
Do Seon Song ◽  
Jong Young Choi ◽  
Sun Hong Yoo ◽  
Hee Yeon Kim ◽  
Myeong Jun Song ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Pilot Study ◽  
Transarterial Chemoembolization

scholarly journals Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Treated With Transarterial Chemoembolization and Sorafenib vs.125Iodine Implantation

2021 ◽  
Vol 11 ◽  
Author(s):  
Hong-Tao Hu ◽  
Jun-Peng Luo ◽  
Guang-Shao Cao ◽  
Zhen Li ◽  
Ming Jiang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Adverse Events ◽  
Portal Vein ◽  
Transarterial Chemoembolization ◽  
Clinical Status ◽  
Objective Response ◽  
Clinical Trial Registration ◽  
Ct Guided ◽  
Seed Implantation ◽  
Sorafenib Group

Background and AimsThis study investigated the feasibility, safety, and efficacy of transarterial chemoembolization (TACE) combined with CT-guided 125iodine seed implantation for treatment of hepatocellular carcinoma (HCC) with first-branch portal vein tumor thrombosis (PVTT).MethodsThis prospective, controlled, multicenter study included HCC patients with Barcelona Clinic Liver Cancer stage C disease and PVTT in the right and/or left portal veins. Patients were treated with either TACE and sorafenib or TACE and CT-guided 125iodine seed implantation and regularly evaluated for clinical response and adverse events, with treatment termination resulting from declining clinical status, loss to follow-up, or death.ResultsThis study demonstrated a significant between-group difference in median overall survival (OS); therefore, it was terminated early. A total of 123 patients were included in this study, with 52 patients in the TACE-sorafenib group and 71 patients in the TACE-125iodine group, without significant differences in baseline characteristics between groups. The median OS was 8.3 months (95% CI: 6.105–10.495) in the TACE-sorafenib group and 13.8 months (95% CI: 9.519–18.081) in the TACE-125iodine group. In a subgroup analysis of type IIa versus type IIb PVTT, the median OS was 17.5 months for type IIa and 7.1 months for IIb in the TACE-125iodine group. The median OS was 9.3 months for IIa and 4.0 months for IIb in the TACE-sorafenib group. Univariate and multivariate analyses confirmed that the PVTT type and treatment strategy were significant independent factors affecting OS. The objective response rates (ORR) for intrahepatic lesions and PVTT showed significant differences between groups. Most patients in both groups experienced minor adverse events related to TACE. The overall incidence of sorafenib-related adverse events or toxic effects was 90.4% in TACE-sorafenib group. In the TACE-125iodine group, the incidence of pneumothorax and minor hepatic subcapsular hemorrhage were 7.04% and 9.86%, respectively.ConclusionsThis study showed that TACE-125iodine treatment significantly enhanced survival of patients with HCC and type II PVTT, especially subtype IIa, with minimal adverse events.Clinical Trial RegistrationChinese Clinical Trials Database, identifier ChiCTR-ONN-16007929.

Sign in / Sign up

Export Citation Format

Share Document